09:24 AM EDT, 09/13/2024 (MT Newswires) -- CureVac ( CVAC ) reported Friday that its CVGBM vaccine triggered a 77% antigen-specific T-cell response in glioblastoma patients following chemo-radiation therapy in an early-stage trial.
The company said that 84% of these respondents developed de novo immune responses, generating T-cell activity where none existed before.
CureVac ( CVAC ) also said the vaccine had a favorable safety profile, with no dose-limiting toxicities detected at the 100 micrograms dose.
Shares of CureVac ( CVAC ) were down nearly 2% in recent Friday premarket activity.
Price: 3.0300, Change: -0.06, Percent Change: -1.94